Plaque Psoriasis in Teens: Deucravacitinib Study

We are evaluating a new medication for adolescents with moderate to severe plaque psoriasis to see if it helps improve their skin condition compared to a placebo. The study also looks at safety and how patients feel about their treatment.

1-2 years 11-15 visits Confirmation phase (III)Post-Trial Drug Access Cost Reimbursement Partially Remote Investigational Medicines OralAllergologyDermatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Deucravacitinib

Deucravacitinib is a substance that blocks a specific immune enzyme to lower inflammation, mainly used for moderate-to-severe plaque psoriasis.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Deucravacitinib

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Universitair Ziekenhuis Gent

Dermatology

Ledeberg, Belgium

Cliniques Universitaires Saint-Luc

Dermatology

Sint-Stevens-Woluwe, Belgium

Centre hospitalier universitaire de Liege

Dermatology

Tilff, Belgium

Sponsor: Bristol-Myers Squibb Services Unlimited Company

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.